Genentech warns of Avastin and Sutent combo in kidney Cancer
This article was originally published in Scrip
Executive Summary
Genentechhas warned US physicians about several cases of microangiopathic haemolytic anaemia (MAHA) seen in patients treated with its anticancer Avastin (bevacizumab) in combination withPfizer's Sutent (sunitinib maleate) in an early trial of metastatic kidney cancer, according to theFDA.